Definium Therapeutics (DFTX) Presentations https://ir.definiumtx.com/news-events/presentations/rss en-us https://d1io3yog0oux5.cloudfront.net/_354426f606269984c271309319e3bc85/mindmed/files/theme/images/logo-sm.png Definium Therapeutics Logo Equisolve Investor Relations Suite <![CDATA[Corporate Presentation February 2026]]> https://d1io3yog0oux5.cloudfront.net/_4f8b86ffb37816caa2330919e1594d8a/mindmed/db/2394/23523/pdf/Definium+Corporate+Presentation+%28Feb+2026%29+v3.pdf Thu, 26 Feb 26 00:00:00 -0500 https://d1io3yog0oux5.cloudfront.net/_4f8b86ffb37816caa2330919e1594d8a/mindmed/db/2394/23523/pdf/Definium+Corporate+Presentation+%28Feb+2026%29+v3.pdf <![CDATA[MM120 for Generalized Anxiety Disorder (GAD): Phase 2b Full Topline Data, ODT PK Bridging Study, Breakthrough Therapy Designation]]> https://d1io3yog0oux5.cloudfront.net/_4f8b86ffb37816caa2330919e1594d8a/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf Thu, 07 Mar 24 00:00:00 -0500 https://d1io3yog0oux5.cloudfront.net/_4f8b86ffb37816caa2330919e1594d8a/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf